Search

Search Constraints

You searched for: Author/Creator Aspord, Caroline

Search Results

1. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. (1st January 2020)

2. BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Issue 11 (24th November 2020)

3. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. (2nd September 2017)

4. Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1−)‐pDC subset negatively correlated with clinical outcomes in melanoma patients. Issue 5 (3rd May 2022)

5. Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes. Issue 11 (9th November 2021)

6. Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells. (13th June 2010)

7. Hepatitis B virus exploits C‐type lectin receptors to hijack cDC1s, cDC2s and pDCs. Issue 12 (8th December 2020)

8. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Issue 7 (July 2019)

10. The avidity of tumor‐specific T cells amplified by a plasmacytoid dendritic cell‐based assay can predict the clinical evolution of melanoma patients. (21st October 2017)